EFX

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics

Retrieved on: 
木曜日, 5月 30, 2024
Patient, News, Liver disease, Food and Drug Administration, Advertising, Fatty liver disease, NASH, Cirrhosis, LLP, Court, EFX, Fibrosis, Cryptocurrency

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Key Points: 
  • Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The firm has recovered hundreds of millions of dollars for investors since its founding in 1995.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Akero’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
  • To learn more about the Akero Therapeutics class action, go to www.faruqilaw.com/AKRO or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext.

DEADLINE ALERT for CMP, EXAI, AKRO, and MBUU: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on: 
木曜日, 5月 30, 2024
Patient, Compass Minerals, Risk, Åkerö, Investment, Suite, FDA, Defendant, Malibu Boats, NAFLD, NASH, Cirrhosis, Ethics, Law, EFX, Compass, Boat, Inflammation, Knowledge, Steatosis, Security (finance)

LOS ANGELES, May 30, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points: 
  • LOS ANGELES, May 30, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
  • Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to [email protected] .
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
  • The Law Offices of Frank R. Cruz, Los Angeles

Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline for Securities Fraud Class Action Lawsuit Filed Against Akero Therapeutics, Inc. (AKRO)

Retrieved on: 
土曜日, 6月 1, 2024
Class Action Lawsuit, Professional Services, Legal, Patient, Non-alcoholic fatty liver disease, News, HERE, FDA, Therapy, Sale, Drug development, Fatty liver disease, Histology, 8-K, NASH, Cirrhosis, LLP, EFX, Fibrosis, District court, Lead, Pharmaceutical industry

The action charges Akero with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.

Key Points: 
  • The action charges Akero with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.
  • As a result of Akero’s materially misleading statements and omissions to the public, Akero’s investors have suffered significant losses.
  • If you suffered Akero losses, you may CLICK HERE or go to: https://www.ktmc.com/new-cases/akero-therapeutics-inc?utm_source=PR&utm_...
    You can also contact attorney Jonathan Naji, Esq.
  • Kessler Topaz Meltzer & Check, LLP encourages Akero investors who have suffered significant losses to contact the firm directly to acquire more information.

DEADLINE ALERT for ADSK, CMP, AKRO, EXAI: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on: 
水曜日, 5月 29, 2024
Patient, Compass Minerals, Class, Risk, Åkerö, Investment, Suite, FDA, Telephone, Defendant, NAFLD, NASH, Cirrhosis, Ethics, Law, EFX, Inflammation, Knowledge, Steatosis

BENSALEM, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points: 
  • BENSALEM, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
  • Investors have until the deadlines listed below to file a lead plaintiff motion.
  • Investors suffering losses on their investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in these class actions at (215) 638-4847 or by email to [email protected] .
  • Law Offices of Howard G. Smith

AKRO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Akero Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
水曜日, 5月 29, 2024
Patient, News, Liver disease, FDA, DSM-IV codes, Sale, Drug development, Person, Fatty liver disease, Research, NASH, Cirrhosis, Court, EFX, Inflammation, Steatosis, Disclosure, Complaint

The Company has yet to generate any revenues because the FDA has not approved any of its drug candidates for sale.

Key Points: 
  • The Company has yet to generate any revenues because the FDA has not approved any of its drug candidates for sale.
  • To finance the Company’s operations, Akero conducted two secondary stock offerings and one at-the-market stock offering during the Class Period, raising over $577 million.
  • If you suffered a loss in Akero you have until June 25, 2024, to request that the Court appoint you as lead plaintiff.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Kirby McInerney LLP Reminds Akero Therapeutics, Inc. (AKRO) Investors of Class Action Filing and Encourages Investors to Contact the Firm

Retrieved on: 
火曜日, 5月 28, 2024
Patient, News, Food and Drug Administration, Fatty liver disease, Research, NASH, Cirrhosis, Court, EFX, District court

Investors have until June 25, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until June 25, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Akero filed with the SEC a Form 8-K and issued a press release stating that the SYMMETRY study had failed to meet its primary endpoint.
  • Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Akero Therapeutics, Inc. (AKRO)

Retrieved on: 
火曜日, 5月 28, 2024
Patient, News, Åkerö, Suite, FDA, NAFLD, NASH, Defendant, Cirrhosis, Court, EFX, Inflammation, GPM, Steatosis

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • On October 10, 2023, Akero announced the results of its Phase 2b SYMMETRY trial, revealing that the study had failed to meet its primary endpoint.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles

Akero Therapeutics, Inc. (AKRO) Investors: June 25, 2024 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP

Retrieved on: 
木曜日, 5月 23, 2024
Patient, Non-alcoholic fatty liver disease, News, HERE, FDA, Therapy, Drug development, Sale, Fatty liver disease, Histology, 8-K, NASH, Cirrhosis, LLP, EFX, Fibrosis, District court, Lead, Pharmaceutical industry

The action charges Akero with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.

Key Points: 
  • The action charges Akero with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.
  • If you suffered Akero losses, you may CLICK HERE or go to: https://www.ktmc.com/new-cases/akero-therapeutics-inc?utm_source=PR&utm_...
    You can also contact attorney Jonathan Naji, Esq.
  • Kessler Topaz Meltzer & Check, LLP encourages Akero investors who have suffered significant losses to contact the firm directly to acquire more information.
  • The class action complaint against Akero, Klobus v. Akero Therapeutics, Inc., et al., Case No.

DEADLINE ALERT for CMP, EXAI, AKRO, and MBUU: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on: 
木曜日, 5月 23, 2024
Patient, Compass Minerals, Risk, Åkerö, Investment, Suite, FDA, Defendant, Malibu Boats, NAFLD, NASH, Cirrhosis, Ethics, Law, EFX, Compass, Boat, Inflammation, Knowledge, Steatosis, Security (finance)

LOS ANGELES, May 23, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points: 
  • LOS ANGELES, May 23, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
  • Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to [email protected] .
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
  • The Law Offices of Frank R. Cruz, Los Angeles

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics

Retrieved on: 
木曜日, 5月 23, 2024
Patient, News, Liver disease, Food and Drug Administration, Advertising, Fatty liver disease, NASH, Cirrhosis, LLP, Court, EFX, Fibrosis, Cryptocurrency

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Key Points: 
  • Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The firm has recovered hundreds of millions of dollars for investors since its founding in 1995.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Akero’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
  • To learn more about the Akero Therapeutics class action, go to www.faruqilaw.com/AKRO or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext.